Company intelligence / Profile preview
Grey Wolf Therapeutics
Oxford, Oxfordshire, United Kingdomgreywolftherapeutics.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
Grey Wolf’s lead asset GRWD5769 has delivered strong results in a Phase 1/2 oncology trial demonstrating proof-of-mechanism and target engagement. The company’s second program GRWD0715 is advancing through preclinical development for autoimmune indications. The company leverages its proprietary antigen modulation platform to address immune dysfunction in oncology and autoimmunity by inhibiting ERAP enzymes to alter antigen presentation on diseased cells. Initial data from ongoing trials are being presented at major scientific meetings such as ASCO in 2024.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Small molecules (notably ERAP1 and ERAP2 inhibitors)MHC Class I-directed therapies (including soluble T cell receptor [TCR] and TCR mimic bispecifics)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer Ventures (investor)collaborations with University of Oxford, Monash University, University of SouthamptonSygnature Discovery as CRO partner
Beyond the preview
Go deeper on Grey Wolf Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grey Wolf Therapeutics.